Video Archives

Understanding Metastatic Castration-Resistant Prostate Cancer

Posted by Shell Liang, PhD | Jun 2024

Shell Liang, PhD, discusses metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that progresses despite androgen deprivation therapy (ADT). Dr. Liang emphasizes the critical need for advanced therapeutic strategies to manage this aggressive cancer subtype effectively.
The presentation reviews the current therapeutic landscape for mCRPC, focusing on second-generation AR pathway inhibitors such as abiraterone and enzalutamide. Additionally, the discussion includes the role of chemotherapeutic agents like docetaxel and cabazitaxel. Dr. Liang also explores emerging treatment modalities, including PARP inhibitors and immunotherapies.
Dr. Liang advocates using genomic profiling to identify actionable mutations and tailor treatments to individual patient profiles. This approach aims to optimize therapeutic efficacy and minimize adverse effects, aligning with the principles of precision medicine.

Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence

Posted by Alan Priester, PhD | Jun 2024

Alan Priester, PhD explores the cutting-edge applications of artificial intelligence (AI) in mapping prostate cancer, emphasizing its transformative potential in precision diagnosis and treatment. Dr. Priester illustrates how AI-driven algorithms analyze vast datasets, offering unprecedented insights into prostate cancer’s spatial and molecular characteristics. These advanced mapping techniques enable the identification of cancerous lesions with remarkable precision, facilitating earlier and more accurate diagnoses.

Moreover, Dr. Priester highlights the role of AI in developing predictive models that forecast disease progression and patient outcomes. These models are instrumental in tailoring individualized treatment plans.

Dr. Priester also addresses the challenges and ethical considerations associated with integrating AI into clinical practice, including data privacy and algorithmic transparency. The discussion extends to the future prospects of AI in prostate cancer care.

Convergent Therapeutics: Next-Generation Targeted Radiotherapies

Posted by Philip Kantoff, MD | Jun 2024

Philip Kantoff, MD, explores the advancements in targeted radiotherapies, emphasizing their potential to revolutionize prostate cancer treatment. He introduces next-generation targeted radiotherapies, such as radioligand therapy, which utilize molecules designed to bind specifically to cancer cell markers, delivering lethal doses of radiation directly to the tumor cells. This approach minimizes damage to surrounding healthy tissues, a limitation of traditional radiotherapy.

Dr. Kantoff highlights convergent therapeutics, which combines targeted radiotherapy with other treatment modalities, including immunotherapy and conventional chemotherapy. Kantoff also addresses the challenges of implementing these advanced therapies in clinical practice.

Clinical Evaluation and Management of Men with Localized and Recurrent Prostate Cancer

Posted by Jan Philipp Radtke, MD, MBA | Jun 2024

Jan Philipp Radtke, MD, MBA, addresses the clinical evaluation and management of men with localized and recurrent prostate cancer, emphasizing a comprehensive and personalized approach to treatment.

Dr. Radtke discusses how advanced imaging techniques, such as multiparametric MRI (mpMRI) and PET imaging (e.g., PSMA-PET), provide detailed anatomical and functional information. He also addresses management strategies for recurrent prostate cancer including salvage radiation therapy, salvage surgery (e.g., radical prostatectomy), systemic therapies such as androgen deprivation therapy (ADT), or novel targeted therapies.

Dr. Radtke emphasizes the importance of multidisciplinary collaboration in managing complex cases of prostate cancer. Collaboration among urologists, radiation oncologists, medical oncologists, and imaging specialists ensures a coordinated approach to treatment planning and monitoring. Regular monitoring through PSA tests and imaging assessments allows for early detection of treatment response or disease progression, enabling timely adjustments to therapeutic strategies.

Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes

Posted by Daniel Margolis, MD | Jun 2024

Daniel Margolis, MD, focuses on standardized MRI and molecular imaging reporting for follow-up in prostate cancer focal therapy. Implementing standardized protocols for imaging evaluation post-focal therapy aims to ensure consistency and reliability across different healthcare settings, facilitate accurate comparison of treatment outcomes, and enable evidence-based decision-making.
Multiparametric MRI (mpMRI) is a cornerstone of the follow-up strategy. By utilizing standardized reporting systems such as the Prostate Imaging Reporting and Data System (PI-RADS), radiologists can systematically assess post-treatment changes, detect residual or recurrent disease, and monitor treatment response. Dr. Margolis also discusses molecular imaging techniques that offer additional insights into treatment response and disease activity at a molecular level. Novel tracers and imaging agents target specific biological markers associated with prostate cancer, enhancing the precision and sensitivity of post-treatment assessments.
Dr. Margolis emphasizes the importance of integrating these imaging modalities into a cohesive framework. This approach not only aids in the early detection of treatment failure or disease recurrence but also guides timely intervention and adjustment of therapeutic strategies.